$1.48
Insights on Apyx Medical Corp
Revenue is down for the last 2 quarters, 15.97M → 14.66M (in $), with an average decrease of 8.2% per quarter
Netprofit is down for the last 3 quarters, -994.0K → -9.60M (in $), with an average decrease of 236.6% per quarter
In the last 1 year, Boston Scientific Corp. has given 42.7% return, outperforming this stock by 91.7%
In the last 3 years, Boston Scientific Corp. has given 72.5% return, outperforming this stock by 157.7%
2.7%
Downside
Day's Volatility :4.0%
Upside
1.33%
18.24%
Downside
52 Weeks Volatility :84.82%
Upside
81.43%
Period | Apyx Medical Corp | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -33.92% | 1.1% | 0.0% |
6 Months | -37.5% | 12.5% | 0.0% |
1 Year | -48.98% | 6.9% | 2.2% |
3 Years | -85.18% | 14.3% | -23.0% |
Market Capitalization | 45.7M |
Book Value | $0.77 |
Earnings Per Share (EPS) | -0.54 |
Wall Street Target Price | 3.63 |
Profit Margin | -35.75% |
Operating Margin TTM | -39.39% |
Return On Assets TTM | -18.8% |
Return On Equity TTM | -58.26% |
Revenue TTM | 52.3M |
Revenue Per Share TTM | 1.51 |
Quarterly Revenue Growth YOY | 16.3% |
Gross Profit TTM | 29.1M |
EBITDA | -19.0M |
Diluted Eps TTM | -0.54 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.78 |
EPS Estimate Next Year | -0.7 |
EPS Estimate Current Quarter | -0.18 |
EPS Estimate Next Quarter | -0.13 |
What analysts predicted
Upside of 145.27%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 16.7M | ↓ 57.09% |
Net Income | 64.0M | ↓ 1364.5% |
Net Profit Margin | 383.61% | ↑ 396.63% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 28.2M | ↑ 68.73% |
Net Income | -19.7M | ↓ 130.7% |
Net Profit Margin | -69.79% | ↓ 453.4% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 27.7M | ↓ 1.57% |
Net Income | -11.9M | ↓ 39.41% |
Net Profit Margin | -42.96% | ↑ 26.83% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 48.5M | ↑ 75.08% |
Net Income | -15.2M | ↑ 27.67% |
Net Profit Margin | -31.33% | ↑ 11.63% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 44.5M | ↓ 8.26% |
Net Income | -23.3M | ↑ 53.14% |
Net Profit Margin | -52.3% | ↓ 20.97% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 52.3M | ↑ 17.61% |
Net Income | -18.7M | ↓ 19.61% |
Net Profit Margin | -35.75% | ↑ 16.55% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 9.1M | ↓ 11.45% |
Net Income | -5.8M | ↑ 6.33% |
Net Profit Margin | -63.58% | ↓ 10.63% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 12.6M | ↑ 38.37% |
Net Income | -6.1M | ↑ 4.66% |
Net Profit Margin | -48.09% | ↑ 15.49% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 12.1M | ↓ 3.72% |
Net Income | -3.5M | ↓ 41.76% |
Net Profit Margin | -29.09% | ↑ 19.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.6M | ↑ 11.75% |
Net Income | -994.0K | ↓ 71.86% |
Net Profit Margin | -7.33% | ↑ 21.76% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 16.0M | ↑ 17.72% |
Net Income | -4.6M | ↑ 365.69% |
Net Profit Margin | -28.98% | ↓ 21.65% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 14.7M | ↓ 8.21% |
Net Income | -9.6M | ↑ 107.54% |
Net Profit Margin | -65.52% | ↓ 36.54% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 95.6M | ↑ 208.54% |
Total Liabilities | 7.8M | ↓ 12.44% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 84.7M | ↓ 11.44% |
Total Liabilities | 13.4M | ↑ 71.09% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 74.1M | ↓ 12.48% |
Total Liabilities | 10.3M | ↓ 23.59% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 68.7M | ↓ 7.27% |
Total Liabilities | 14.7M | ↑ 43.5% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 51.8M | ↓ 24.66% |
Total Liabilities | 14.0M | ↓ 4.96% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 79.2M | ↑ 53.05% |
Total Liabilities | 52.3M | ↑ 274.18% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 55.3M | ↓ 7.07% |
Total Liabilities | 13.1M | ↓ 1.93% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 51.8M | ↓ 6.32% |
Total Liabilities | 14.0M | ↑ 7.13% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 56.8M | ↑ 9.67% |
Total Liabilities | 20.6M | ↑ 47.12% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 62.4M | ↑ 9.94% |
Total Liabilities | 25.7M | ↑ 24.92% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 59.4M | ↓ 4.78% |
Total Liabilities | 25.9M | ↑ 0.64% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 79.2M | ↑ 33.3% |
Total Liabilities | 52.3M | ↑ 102.31% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -21.0M | ↑ 467.25% |
Investing Cash Flow | 29.3M | ↓ 4795.67% |
Financing Cash Flow | -2.5M | ↑ 1292.18% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -18.5M | ↓ 12.07% |
Investing Cash Flow | 60.5M | ↑ 106.62% |
Financing Cash Flow | 147.0K | ↓ 105.9% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -16.1M | ↓ 13.04% |
Investing Cash Flow | -581.0K | ↓ 100.96% |
Financing Cash Flow | -73.0K | ↓ 149.66% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -10.4M | ↓ 34.96% |
Investing Cash Flow | -723.0K | ↑ 24.44% |
Financing Cash Flow | 24.0K | ↓ 132.88% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -20.3M | ↑ 94.09% |
Investing Cash Flow | -1.0M | ↑ 39.7% |
Financing Cash Flow | 217.0K | ↑ 804.17% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.4M | ↓ 8.72% |
Investing Cash Flow | -188.0K | ↓ 53.12% |
Financing Cash Flow | 127.0K | ↑ 6250.0% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.5M | ↓ 15.49% |
Investing Cash Flow | -142.0K | ↓ 24.47% |
Financing Cash Flow | -10.0K | ↓ 107.87% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.9M | ↓ 58.48% |
Investing Cash Flow | -110.0K | ↓ 22.54% |
Financing Cash Flow | 8.1M | ↓ 81220.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.9M | ↑ 157.95% |
Investing Cash Flow | 7.1M | ↓ 6564.55% |
Financing Cash Flow | 46.0K | ↓ 99.43% |
Sell
Neutral
Buy
Apyx Medical Corp is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Apyx Medical Corp | 17.19% | -37.5% | -48.98% | -85.18% | -69.2% |
Stryker Corporation | -3.86% | 30.27% | 12.73% | 26.98% | 78.91% |
Dexcom, Inc. | -1.59% | 63.45% | 11.22% | 31.69% | 366.88% |
Boston Scientific Corp. | 7.32% | 46.46% | 42.68% | 72.49% | 95.05% |
Abbott Laboratories | -2.84% | 13.74% | -1.71% | -12.8% | 36.06% |
Medtronic Plc | -3.97% | 14.22% | -10.66% | -38.23% | -7.98% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Apyx Medical Corp | NA | NA | NA | -0.78 | -0.58 | -0.19 | NA | 0.77 |
Stryker Corporation | 40.64 | 40.64 | 2.92 | 11.85 | 0.18 | 0.07 | 0.01 | 48.92 |
Dexcom, Inc. | 102.89 | 102.89 | 2.53 | 1.76 | 0.26 | 0.06 | NA | 5.37 |
Boston Scientific Corp. | 64.48 | 64.48 | 1.8 | 2.25 | 0.09 | 0.04 | NA | 13.16 |
Abbott Laboratories | 33.52 | 33.52 | 5.99 | 4.31 | 0.15 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 25.81 | 25.81 | 1.52 | 5.2 | 0.08 | 0.04 | 0.03 | 38.95 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Apyx Medical Corp | Buy | $45.7M | -69.2% | NA | -35.75% |
Stryker Corporation | Buy | $127.4B | 78.91% | 40.64 | 15.44% |
Dexcom, Inc. | Buy | $54.6B | 366.88% | 102.89 | 14.95% |
Boston Scientific Corp. | Buy | $101.4B | 95.05% | 64.48 | 11.18% |
Abbott Laboratories | Buy | $186.7B | 36.06% | 33.52 | 13.96% |
Medtronic Plc | Buy | $107.9B | -7.98% | 25.81 | 13.0% |
Archon Capital Management LLC
Royce & Associates, LP
AIGH Capital Management, LLC
Vanguard Group Inc
RTW INVESTMENTS, LLC
Taylor Frigon Capital Management LLC
Apyx Medical Corp’s price-to-earnings ratio stands at None
Read Moreapyx medical corporation, a energy technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. it operates in two segments, advanced energy and original equipment manufacturing (oem). the company develops j-plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. it markets and sells helium plasma technology under the renuvion brand name in the cosmetic surgery market and under the j-plasma brand name in the hospital surgical market. the company's renuvion cosmetic technology enables plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue; and the j-plasma system allows surgeons to operate in eliminating unintended tissue trauma. it also designs, develops, manufactures, and sells electrosurgical and oem generators and related accessories for medical device manufacturers. the company was formerly known as bovie medical corporation and changed
Organization | Apyx Medical Corp |
Employees | 252 |
CEO | Mr. Charles D. Goodwin II |
Industry | Health Technology |